Dysregulation of the angiopoietin–Tie-2 axis in sepsis and ARDS

Samir M Parikh

Division of Nephrology; Center for Vascular Biology Research; Beth Israel Deaconess Medical Center and Harvard Medical School; Boston, MA USA

Keywords: angiopoietin-1, angiopoietin-2, Tie-2, Tie-1, VE-PTP, VE-cadherin, permeability, vascular leakage, sepsis, infection, acute respiratory distress syndrome

Dynamic changes in microvascular endothelial structure and function are pivotal in the acute inflammatory response, the body's rapid, coordinated effort to localize, sequester, and eliminate microbial invaders at their portal of entry. To achieve this, the endothelium becomes leaky and inflamed, providing innate immune cells and humoral effector molecules access to the site of infection. During sepsis this locally adaptive response becomes manifest throughout the body, leading to dangerous host consequences. Increased leakiness in the pulmonary circulation contributes to acute respiratory distress syndrome (ARDS), a complication of sepsis associated with 40% mortality. Understanding the molecular governance of vascular leak and inflammation has major diagnostic, prognostic, and potentially therapeutic implications for this common and pernicious disease. This review summarizes results from cell-based experiments, animal models, and observational human studies; together, these studies suggest that an endothelial receptor called Tie2 and its ligands, called angiopoietins, form a signaling axis key to the vascular dyshomeostasis that underlies sepsis.

Introduction

The vascular endothelium constitutes the innermost lining of the body's circulatory system and the largest tissue in the body. In capillaries, this cell is the primary barrier between elements in the blood and the parenchymal cells that rely on perfusion to deliver nutrients and remove wastes. Rather than serving as a static structure, microvascular endothelium performs several essential functions: maintenance of a semipermeable barrier to water and biomolecules, regulation of leukocyte diapedesis through the expression of apical adhesion molecules, modulation of vascular tone, and fine-tuning of hemostasis. The manifestations of tissue inflammation readily apparent to the novice physical examiner—rubor, dolor, calor, and tumor—attest to the centrality and prominence of microvascular changes in inflammation. Yet, in the field of sepsis, the molecular pathogenesis of microvascular disruption has been relatively under-studied, with the focus instead being the initial interactions of innate immune effectors vs. invasive microbes.

Why the Cytokine Theory and the “Vasculo-Centric View” of Sepsis are not Mutually Exclusive

In the 1980s, investigations led by Beutler, Cerami, Dinarello, Tracey, and others identified the first host molecules responsible for the fever and shock response to bacteria: tumor necrosis factor-α (TNFα), interleukin-1 (IL-1), and interferon-gamma (IFNγ). In one landmark paper, Tracey and colleagues used three baboons intravenously injected with E. coli to demonstrate that neutralization of TNFα was sufficient to prevent death, without the administration of antibiotics. This startling finding spawned a revolution in our understanding of sepsis, focusing the research community's attention on an expanding list of cytokine mediators of the septic phenotype that were potentially targetable with recombinant drugs.

Against this backdrop of excitement, the first negative clinical trials of TNFα neutralization in sepsis were a grave disappointment. While follow-up pre-clinical studies suggested that better animal models of sepsis would have revealed the ineffectiveness of TNFα neutralization, only 4% of subjects in the highest drug arm of one of these trials had detectable circulating levels of TNFα at the time of enrollment. More recently, a large Phase 3 trial of a drug that inhibits the Toll-like receptor 4 (TLR4) failed to show benefit among patients with sepsis. TLR4 is the body's primary sensor of gram-negative endotoxin. Its discovery was recognized by the 2011 Nobel Prize in Medicine because this research is considered foundational in immunology.

Do these examples imply that TNFα (or any other cytokine or bacterial product) does not contribute to sepsis pathogenesis in humans? Not at all. Rather, they illustrate the unique heterogeneity of sepsis as it comes through hospitals' doors. Sufferers present to medical attention at different times in their illness with different pathogens and portals of entry, bearing genetic differences in their acute inflammatory response that are further compounded by age and comorbidities. By the time patients present for medical care, levels of early mediators like endotoxin or TNFα may well have waned.

The remarkable heterogeneity of early sepsis narrows down to a handful of near-stereotypical features as the patient approaches death: the development of shock and the progressive dysfunction
of key organs. Working backward from this final pathway reveals a commonality—namely, that endothelial functions have become deranged. In the lungs, microvessel leak contributes to pulmonary edema. In the kidneys, leukocyte adhesion to glomerular and peritubular capillaries impairs perfusion and filtration. In the macrocirculation, inability to regulate vascular tone necessitates vasopressor drugs. Thus, based on empiricism alone, one could argue that patients with sepsis die not of the early induction of inflammatory cytokines, but rather, the late sequelae that impact the vasculature.

While such a distinction may be semantic, there are several practical implications. Focusing investigative effort on the septic vasculature may lead to the identification of novel molecular contributors to the disease. Measuring such molecules in patients may help segregate severe sepsis from milder forms or even identify individuals about to progress in disease severity. Intervening on such vascular molecular pathways may be more feasible than cytokine blockade simply because patients present hours to days after infection develops, not the timeframe of minutes to hours used in most pre-clinical models. By this “late” time point, levels of acute phase reactants such as TNFα have likely spiked and abated, setting off a biological chain reaction that culminates in clinical disease, but no longer present for neutralization in the bloodstream. Below, the author will summarize studies that implicate angiopoietin-1 and -2 (Angpt-1, -2) and their receptor, Tie-2, as an important candidate vascular pathway in sepsis.

Introduction to ANGPTs and TIEs

In 1992, Dumont and colleagues cloned a new transmembrane tyrosine kinase from endothelial DNA called tek.9 The gene was later re-named Tie-2 after Sato et al. independently cloned both Tie-2 and the related receptor Tie-1 from a brain microvasselecDNA library.10 Their PCR-based search for Tie-2 was in turn, based on a 1992 report from Alitalo’s group describing Tie-1.11 Subsequent gene targeting experiments in mice revealed that Tie-2 expression was highly restricted to the endothelium and that its expression was essential to blood vessel maturation during embryonic development.12 The homology of the extracellular domain to other receptor tyrosine kinases suggested the existence of peptide ligands. Through an innovative adaptation of expression cloning, scientists led by George Yancopoulos identified Angpt-1 and, soon thereafter, Angpt-2.13,14

Angpt-1 is largely made and secreted by peri-endothelial cells and platelets whereas Angpt-2 is synthesized in endothelium where pre-formed protein is stored for rapid release in granules called Weibel–Palade bodies.15 To a lesser extent, Angpt-2 is also made by macrophages. Both bind Tie-2 with nanomolar affinity, and excess Angpt-2 competes Angpt-1 off the receptor, suggesting that the latter is a competitive antagonist of the former on endothelial cells.16 Crystallographic results show that the C-terminal fibrinogen domain common to Angpt-1 and Angpt-2 binds to an “arrowhead” structure within the ectodomain of Tie-2 composed of two immunoglobulin folds and three epidermal growth factor domains.16,17 While the difference in downstream signaling achieved by these ligands is not completely explained, biochemical studies suggest that an N-terminal region unique to Angpt-1 favors its multimerization into large aggregates, leading to more intense Tie-2 clustering and greater cross-phosphorylation.18 Consistent with this agonist-antagonist framework, the Angpt-1 knockout mouse and the Angpt-2 transgenic mouse phenocopy the vascular defects of the Tie-2 knockout mouse. Results described in the next section strongly suggest that Angpt-1 and Angpt-2 also have opposing functions in the setting of inflammation (Fig. 1).

Other molecules in the Angpt–Tie pathway include a paralog of Angpt-1 called Angpt-3/4 that also activates Tie-219 and a
paralog of Tie-2 called Tie-1 that has no agreed-upon ligand and is thought to inhibit Tie-2 signaling by heterodimerizing with it. A naturally occurring extracellular cleavage product of Tie-2 may exert dominant-negative effects, and a transmembrane tyrosine phosphatase called VE-PTP also attenuates Tie-2 signaling by removing phosphate from key tyrosines in Tie-2’s intracellular domain. Specific integrins appear to be alternative receptors for Angpt. Finally, a growing number of Angpt-like proteins have been cloned, but they do not appear to act on endothelial cells per se or signal through Tie-2. To summarize the most rigorously tested hypotheses in a straightforward fashion, the rest of this review will focus on Angpt-1, Angpt-2, and Tie-2.

**Tie-2 Signaling and Functional Consequences in Experimental Inflammation**

In 1997, Wong, et al. showed that Tie-2 was not only expressed in the mature, non-angiogenic adult vasculature, but was also substantially phosphorylated. This important description suggested that Tie-2 signaling aided one or more maintenance functions in the mature endothelium. Based on the fact that Tie-2 expression was necessary for nascent blood vessels to develop into mature vessels during embryogenesis, collaborative studies led by Yancopoulos and McDonald hypothesized that Tie-2 signaling may similarly “stabilize” non-angiogenic blood vessels. Using Angpt-1 transgenic mice and adenoviral Angpt-1 gene transfer, they showed that excess Angpt-1 prevented vascular leak induced by disparate stimuli, including vascular endothelial growth factor (VEGF), mustard oil, and serotonin.

The list of permeability mediators against which Angpt-1 defends barrier function was soon extended to gram-negative endotoxin. Witzenbichler et al. demonstrated that excess Angpt-1 confers a survival benefit in murine endotoxemia associated with less vascular leakage and less cellular inflammation. Mammoto et al. showed that Angpt-1 prevents endotoxin-induced leak and inflammation by signaling through phosphatidylinositol-3-kinase (PI3-K) and Akt to regulators of the endothelial actin cytoskeleton called Rac1 and RhoA. This work provided the mechanistic complement to a live microscopy study of rat tracheal microvessels performed by Baffert et al. that strongly implicated junctional and cytoskeletal remodeling in Angpt-1-mediated barrier defense. Finally, Brindle’s group showed that Angpt-1 application to endothelial cells induced an inhibitor of the canonical inflammatory transcription factor NFkB. Together, these results described a novel phenomenon—vascular barrier defense against diverse ligands mediated by Angpt-1—and a molecular mechanism to account for this remarkable effect (Fig. 2). More recent studies from the laboratories of Vestweber, Deutsch, Koh, Olsen, Mochizuki and Altalal present compelling evidence for important phenotypic differences arising from Tie-2’s localization within the cell membrane and its downstream signaling partners.

During this period, a converse set of findings for Angpt-2 was emerging from several laboratories. In 2006, Parikh et al. reported that circulating Angpt-2 was elevated in humans with severe sepsis and that acute disruption of Tie-2 weakened endothelial barrier function. Their findings suggested a positive association with sepsis-associated ARDS and a mechanism whereby Tie-2 inhibition forced the contraction of endothelial cells through remodeling of the cytoskeleton. Shortly thereafter, a group led by Augustin used knockout mice and siRNA to show that Angpt-2 sensitizes the endothelium to inflammation by dose-dependently inducing vascular cell adhesion molecule-1 (VCAM-1), and an independent study from teams led by Elias and Matthy used knockout mice, siRNA, and bronchoalveolar lavage samples from people with ARDS to implicate Angpt-2 in inflammatory acute lung injury. Augustin’s group also showed that Angpt-2 synthesized by endothelial cells is stored in Weibel–Palade bodies and rapidly exocytosed upon stimulation with different inflammatory mediators such as thrombin. Since sepsis in humans has been associated with a sustained elevation in Angpt-2, there is likely ongoing transcription and translation to generate Angpt-2 protein de novo, but the mechanisms are not well-understood. Finally, two recent reports suggest that Angpt-2 may actually be beneficial in acute infection-related inflammation, perhaps through an agonistic effect on Tie-2, but additional data may be needed to understand why these results refute the larger literature.

Relatively few experimental studies in sepsis have focused directly on Tie-2, where the prediction would be that reduced Tie-2 signaling is associated with adverse outcomes. Stewart’s group applied intratracheal endotoxin to show that Tie-2 heterozygous mice develop worse lung injury and earlier mortality than wild-type littermates. They also reported that levels of total and phosphorylated Tie-2 were depressed in whole lung homogenates of endotoxin-challenged mice. Using systemic endotoxin to model sepsis, David et al. also observed a decrease in total Tie-2 expression...
and a fall in the phosphorylated fraction of the receptor, arguing for a “two-hit” model of impaired Tie-2 signaling that results from a combination of receptor antagonism and reduced expression.48

David and colleagues also applied a peptide mimetic of Angpt-1 (identified by phage display experiments and bearing no sequence homology to Angpt-1) called vasculotide49 to endotoxemic mice and showed an improvement in Tie-2 expression, Tie-2 phosphorylation, endothelial barrier function, vascular permeability, and survival in endotoxemia. This same group also applied calcification-puncture to mice and observed similar beneficial effects of vasculotide, even demonstrating a rescue effect after sepsis induction.50 While the therapeutic potential of vasculotide may one day be realized, the mechanistic implication of these experiments is clear: by showing that a completely non-homologous Tie-2 activator achieves similar molecular and physiological effects to Angpt-1 in septic mice, the vasculotide data independently corroborate the importance of Tie-2 signaling (vs. non-canonical angiopoietin receptors such as integrins) in septic vascular phenotypes.

**Proof-of-Concept Studies in Humans**

No targeted therapies and few biomarkers inspired by pre-clinical studies have successfully translated to advances in the care of patients with sepsis or ARDS. There are many reasons for the chasm between mouse studies and human disease.51 As proposed above, the focus on translating innate immune effectors may be one factor in this divide: (1) the circulating leukocyte pool in mice is shifted toward lymphocytes whereas human WBC counts are dominated by neutrophils, (2) molecular aspects of acute inflammation may be different as well,52 and finally, (3) the temporopatellar complexity and redundancy of this highly evolved response may be impossible to summate into a single measurement or target. Early human testing of pre-clinical observations may streamline the process of molecular discovery and application in critical illness. The availability of commercial ELISAs for Angpt-1 and Angpt-2 has facilitated efforts to validate the involvement of this pathway in human sepsis and ARDS (Table 1).

Intriguing genetic and biochemical evidence suggests that tonic Tie-2 activation in the mature quiescent vasculature could be a ligand-independent phenomenon.53,54 Nonetheless, Angpt-1 is poised to mediate this effect since it is made and secreted by platelets and by cells adjacent to the endothelium. The N-terminal region of Angpt-1 may even promote local adherence to the extracellular matrix,29 leading to a high tissue concentration despite low circulating levels. In sepsis, ARDS, and related conditions, circulating Angpt-1 appears to be suppressed (Table 1).55,56 consistent with the experimental observation that Tie-2 phosphorylation falls. The mechanisms driving Angpt-1 suppression in these settings are not known. However, the magnitude of Angpt-1’s decline tends to be 2- to 3-fold or less, compared with ~5- to 20-fold increase in circulating Angpt-2 observed under similar conditions. As shown in Table 1, an Angpt-2/Angpt-1 ratio may outperform Angpt-1 alone in clinical correlations. In addition to non-covalent interactions favoring Angpt-1’s adherence to the matrix, some studies of circulating Angpt-1 may also be confounded by its measurement in serum, where ex vivo platelet aggregation may release Angpt-1 and lead to artifactual elevation.37

Circulating Angpt-2 concentrations have a much broader dynamic range than Angpt-1. In 2006, Parikh et al. reported 10- to 20-fold elevation in circulating Angpt-2 among individuals with severe sepsis at the time of ICU admission compared with those with uncomplicated sepsis and hospitalized controls. The authors noted that subjects with severe sepsis developed higher peak Angpt-2 concentrations than those with uncomplicated sepsis and further observed that individuals with impaired lung gas exchange had higher peak Angpt-2 values than those with normal gas exchange.39 Combined with animal and cellular data, the authors speculated that Angpt-2 may be both a marker and mediator of vascular leakage during sepsis. Studies led by Bhandari and van der Heijden independently corroborated these concepts by showing accumulation of Angpt-2 in the alveolar fluid of patients with acute lung injury (ALI) and a positive correlation between Angpt-2 and quantitative measures of fluid extravasation in the lungs.40,58

The association between high Angpt-2 and ALI/ARDS has been borne out in surgical populations,49 non-infection-associated ALI,60 and in primary graft dysfunction following lung transplantation.61 The link between Angpt-2 and pulmonary vascular leak may be coincidental or a product of the ease with which hyperpermeability in this vascular bed can be detected. It could also relate to the fact that the lung contains such an extensive capillary network that endothelial cells—i.e., cells expressing the Tie-2 receptor as well the primary source of Angpt-2—constitute nearly 10% of the total cell population.

Further evidence linking Angpt-2 to acute vascular leakage throughout the body has come from studies of patients receiving the immune stimulator IL-2 for cancer therapy—whose dose-limiting toxicity is shock from vascular hyperpermeability—and from careful correlations of fluid balance in the ICU to serial Angpt-2 values.60,62,63 Finally, induction of circulating Angpt-2 has also been reported in other conditions associated with acute vascular leakage, including severe malaria,54,64 systemic anthrax (in baboons, not yet studied in humans),65 acute pancreatitis,66 polytrauma,68,69 and bacterial toxic shock syndrome.70

**Possibilities for Applying ANGPTs to Improve Patient Care**

Is Angiopoietin-2 or Angpt-2/Angpt-1 a biomarker of sepsis or ARDS? Measurement of these proteins could be used for diagnosis and/or prognosis in afflicted or at-risk individuals for critical illness. This kind of information could be particularly useful in resource-limited settings, where a quantitative, operator-independent tool could be deployed for triaging incoming patients to more intensive care and monitoring, such as battlefields. They could help risk-stratify patients in future ICU-based clinical trials to segregate patients into pathophysiological groups, even for interventions that do not per se intersect with the Angpt–Tie-2 axis. Criteria identified by Sir Austin Bradford Hill, an epidemiologist famous for linking cigarette smoke to lung cancer, may be instructive for considering the Angpt’s in a clinical application. These criteria are bolded below.71
Table 1. Human findings in the Angpt–Tie2 axis related to sepsis and ARDS

<table>
<thead>
<tr>
<th>Author</th>
<th>Setting</th>
<th>No. of subjects*</th>
<th>Main findings</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parikh39</td>
<td>ICU, sepsis</td>
<td>22</td>
<td>• Angpt-2 ↑ in severe sepsis &lt;br&gt;• Angpt-2 ↑ with low P/F ratio</td>
<td>2006</td>
</tr>
<tr>
<td>Bhandari41</td>
<td>ICU, ALI</td>
<td>3–4</td>
<td>• Angpt-2 ↑ in ALI &lt;br&gt;• Angpt-2 ↑ in ALI alveolar fluid</td>
<td>2006</td>
</tr>
<tr>
<td>Orfanos78</td>
<td>ICU, sepsis</td>
<td>13–18</td>
<td>• Angpt-2 ↑ in severe sepsis &lt;br&gt;• Angpt-2 correlates with TNF</td>
<td>2007</td>
</tr>
<tr>
<td>Giuliano59</td>
<td>Pediatric ICU, sepsis</td>
<td>61</td>
<td>• Angpt-2 ↑ at ICU admission in septic shock &gt; sepsis &gt; SIRS &lt;br&gt;• Angpt-1 ↓ in septic shock</td>
<td>2007</td>
</tr>
<tr>
<td>Gallagher59</td>
<td>ICU, ALI</td>
<td>18</td>
<td>• Angpt-2 ↑ in future non-survivors of ALI/ARDS</td>
<td>2008</td>
</tr>
<tr>
<td>Ganter66</td>
<td>ED/ICU/ OR, trauma</td>
<td>208</td>
<td>• Angpt-2 ↑ within 30 min post-injury and correlates with injury severity, shock, and adverse outcomes</td>
<td>2008</td>
</tr>
<tr>
<td>van der Heijden58</td>
<td>ICU, sepsis</td>
<td>22</td>
<td>• Angpt-2 ↑ in sepsis, ALI &lt;br&gt;• Angpt-2 correlates with measures of pulmonary vascular leakage</td>
<td>2008</td>
</tr>
<tr>
<td>Giamarellos-Bourboulis69</td>
<td>ICU, trauma, sepsis</td>
<td>16 with trauma and sepsis</td>
<td>• Angpt-2 ↑ upon advent of sepsis and correlates with adverse outcomes</td>
<td>2008</td>
</tr>
<tr>
<td>Kuempers73</td>
<td>ICU, sepsis</td>
<td>43</td>
<td>• Angpt-2 ↑ healthy &lt; sepsis &lt; septic shock &lt;br&gt;• Angpt-2 correlates with clinical severity, outcomes &lt;br&gt;• No trend for Angpt-1</td>
<td>2008</td>
</tr>
<tr>
<td>Siner79</td>
<td>ICU, sepsis</td>
<td>24</td>
<td>• Angpt-2 in septic non-survivors &gt; septic survivors &lt;br&gt;• Angpt-2 correlates with IL-6 and severity of illness</td>
<td>2009</td>
</tr>
<tr>
<td>Su75</td>
<td>ICU, ARDS</td>
<td>449</td>
<td>• 9 tag SNP survey over ANGPT2 locus yields 1 common variant associated with ARDS</td>
<td>2009</td>
</tr>
<tr>
<td>Kuempers80</td>
<td>ICU, sepsis</td>
<td>21 in ICU</td>
<td>• in ICU, Angpt-2 ↑ in future non-survivors</td>
<td>2009</td>
</tr>
<tr>
<td>van der Heijden83</td>
<td>ICU, septic shock</td>
<td>50</td>
<td>• Angpt-2 correlates with fluid balance and pulmonary dysfunction</td>
<td>2009</td>
</tr>
<tr>
<td>Ebihara81</td>
<td>ICU, septic shock</td>
<td>12</td>
<td>• Angpt-2 ↑ in septic shock non-survivors &lt;br&gt;• Angpt-1 ↓ in septic shock non-survivors</td>
<td>2009</td>
</tr>
<tr>
<td>Kuempers82</td>
<td>ICU, RRT</td>
<td>117</td>
<td>• Angpt-2 ↑ with more severe AKI &lt;br&gt;• Angpt-2 predicts mortality when RRT needed</td>
<td>2010</td>
</tr>
<tr>
<td>Davis83</td>
<td>ICU, wards, sepsis</td>
<td>83</td>
<td>• Angpt-2 ↑ proportional to sepsis severity &lt;br&gt;• Angpt-2 inversely to NO-dependent vasoreactivity</td>
<td>2010</td>
</tr>
<tr>
<td>Mankhambo84</td>
<td>Pediatric ICU, wards, sepsis</td>
<td>293</td>
<td>• Angpt-2 ↑ in future non-survivors &lt;br&gt;• Angpt-1 ↓ in future non-survivors &lt;br&gt;• in multivariate analysis, ↑ Ang-1 associated with mortality</td>
<td>2010</td>
</tr>
<tr>
<td>Alves85</td>
<td>Febrile neutropenia</td>
<td>10</td>
<td>• Angpt-2 and Angpt-2/Angpt-1 ↑ 48 h after fever onset in those developing septic shock</td>
<td>2010</td>
</tr>
<tr>
<td>Ricciuto86</td>
<td>ICU, sepsis</td>
<td>70</td>
<td>• Angpt-1 ↑ at ICU admission associated with mortality &lt;br&gt;• Angpt-2 correlates with clinical severity and endothelial markers</td>
<td>2011</td>
</tr>
<tr>
<td>Page70</td>
<td>ICU, strep toxic shock</td>
<td>37</td>
<td>• Angpt-2 ↑ in strep toxic shock syndrome &lt;br&gt;• Angpt-1 ↑ in strep toxic shock syndrome</td>
<td>2011</td>
</tr>
</tbody>
</table>

ICU, intensive care unit; ED, emergency department; OR, operating room; AKI, acute kidney injury; RRT, renal replacement therapy; P/F, plasma oxygen/fraction inspired oxygen; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; SIRS, systemic inflammatory response syndrome; SNP, single nucleotide polymorphism. *Number in main experimental group.

The experimental results outlined above highlight the biological plausibility of Angpt-2-driven features in sepsis and ARDS. Independent studies consistently report a strong association between higher Angpt-2 concentrations and disease severity measured variously by a clinical score of organ impairment, duration of ICU care, development of shock, or
inpatient mortality. This association is proportional to sepsis severity in studies from different investigators. The marked induction of circulating Angpt-2 appears to be specific to conditions of acute vascular injury and leakage ranging from sepsis to anthrax as noted above. Finally, the induction of Angpt-2 clearly precedes adverse outcomes, a point strongly illustrated in an emergency-ward based study of 270 adults suspected of infection in whom circulating Angpt-2 measured within the first hour of hospitalization predicted inpatient mortality with a receiver-operator characteristics (ROC) area under the curve of 0.91. Larger studies will be needed to evaluate the utility of Angpt-2 cut-off values. In further support of temporal precedence, targeted genetic scans suggest that common variants in the ANGPT-2 locus that may affect gene expression are associated with ALI/ARDS.

Since the initial elevation in Angpt-2 may be sustained for several days in severely ill patients, Angpt-2 may be more easily targeted for antibody-mediated neutralization compared with cytokines such as TNFα. Partial genetic deletion of Angpt-2 appears to be sufficient to attenuate inflammation, improve organ function, reduce vascular leak, and improve survival. Antibodies specific for Angpt-2 have also been shown to prevent septic plasma-induced microvascular endothelial barrier dysfunction and to attenuate vascular remodeling and inflammation in a chronic lung infection model. Theoretically, Angpt-2 neutralization should restore basal Tie-2 phosphorylation, though this remains to be formally demonstrated. Other therapeutic approaches could drive Tie-2 activation to supra-physiological levels—e.g., recombinant Angpt-1 itself, a derivative thereof such as COMP-Angpt-1, an unrelated agonist such as vasculotide, or administration of cells that express Angpt-1, or even inhibition of the tyrosine phosphatase VE-PTP.

Table 1. Human findings in the Angpt–Tie2 axis related to sepsis and ARDS (continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Setting</th>
<th>No. of subjects*</th>
<th>Main findings</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer46</td>
<td>ICU, ALI</td>
<td>822</td>
<td>• 50K SNP array for cardiovascular genes identifies two common variants in ANGPT2 locus associated with ALI</td>
<td>2011</td>
</tr>
</tbody>
</table>
| Calfee50 | ICU, ALI | 931 | • Angpt-2↑ in future non-survivors of non-infection ALI  
• Angpt-2↑ with fluid-conservative therapy | 2012 |
| David72 | ED, suspected infection | 270 | • Angpt-2↑ detectable within 1st h of hospitalization  
• 1st h Angpt-2 associated with disease severity  
• 1st h Angpt-2 predicts future shock and mortality | 2012 |

ICU, intensive care unit; ED, emergency department; OR, operating room; ALI, acute kidney injury; RRT, renal replacement therapy; P/F, plasma oxygen/fraction inspired oxygen; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; SIRS, systemic inflammatory response syndrome; SNP, single nucleotide polymorphism. *Number in main experimental group.

Table 1.

<table>
<thead>
<tr>
<th>Author</th>
<th>Setting</th>
<th>No. of subjects*</th>
<th>Main findings</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer46</td>
<td>ICU, ALI</td>
<td>822</td>
<td>• 50K SNP array for cardiovascular genes identifies two common variants in ANGPT2 locus associated with ALI</td>
<td>2011</td>
</tr>
</tbody>
</table>
| Calfee50 | ICU, ALI | 931 | • Angpt-2↑ in future non-survivors of non-infection ALI  
• Angpt-2↑ with fluid-conservative therapy | 2012 |
| David72 | ED, suspected infection | 270 | • Angpt-2↑ detectable within 1st h of hospitalization  
• 1st h Angpt-2 associated with disease severity  
• 1st h Angpt-2 predicts future shock and mortality | 2012 |

ICU, intensive care unit; ED, emergency department; OR, operating room; ALI, acute kidney injury; RRT, renal replacement therapy; P/F, plasma oxygen/fraction inspired oxygen; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; SIRS, systemic inflammatory response syndrome; SNP, single nucleotide polymorphism. *Number in main experimental group.

Summary

The cloning of Tie-2 was reported just over 20 years ago, and its major ligands were identified in the late 1990s. Since then, an accelerating body of work has demonstrated fascinating biology related to this pathway in cancer, vascular patterning, angiogenesis, lymphangiogenesis, inflammation, and vascular permeability. Drugs based on the Angpt–Tie-2 pathway have already been developed and are matriculating through clinical trials. The breathtaking pace at which clinical applications have been sought attests to the intense interest these proteins have generated in the biomedical community. In the field of sepsis, the traditional focus on early innate immune aspects of the host response is gradually broadening to consider the penultimate vascular changes that directly lead to the most damaging clinical manifestations of this disease. The Angpt–Tie-2 axis is a particularly strong candidate vascular pathway based on the remarkable convergence of experimental and human observational data. Tie-2 signaling impairment—via Angpt-2 induction and other potential mechanisms—may potentiate the vascular leak and inflammation induced by the early cytokine wave of sepsis. The ultimate proof of these concepts will require carefully designed clinical trials.

Disclosure of Potential Conflicts of Interest

SMP is listed as an inventor on disclosures regarding angiopoietins filed with Beth Israel Deaconess Medical Center.

Acknowledgments

The author would like to thank Drs Ananth Karumanchi, Sascha David, and Chandra Ghosh for critical feedback. SMP is supported by NIH grants R01-HL093234 and R01-DK095072 and by the American Diabetes Association (1-13-BS-141).


34. Patent No. 5,718,045, Method for increasing blood flow to the eye, Aggress, 1998